Malta - English - Medicines Authority

ebewe pharma gmbh nfg. kg - oxaliplatin 5 mg/ml - powder for solution for infusion

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi oncology plc - oxaliplatin - pdr for soln for infusion - 5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - oxaliplatin - concentrate for soln for inf - 5 mg/ml - platinum compounds

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - oxaliplatin - concentrate for solution for infusion - 5mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare polska sp. z o.o. - oxaliplatin - concentrate for solution for infusion - 5mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 100mg;   - powder for infusion - 100 mg - active: oxaliplatin 100mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 100mg - powder for injection - 100 mg - active: oxaliplatin 100mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 5 mg/ml - solution for injection - 5 mg/ml - active: oxaliplatin 5 mg/ml excipient: water for injection - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.